Protein tyrosine kinases and cancer - PubMed (original) (raw)

Review

Protein tyrosine kinases and cancer

K S Kolibaba et al. Biochim Biophys Acta. 1997.

No abstract available

PubMed Disclaimer

Similar articles

• Signal transduction by wild-type and leukemogenic Abl proteins.
  Raitano AB, Whang YE, Sawyers CL. Raitano AB, et al. Biochim Biophys Acta. 1997 Dec 9;1333(3):F201-16. doi: 10.1016/s0304-419x(97)00023-1. Biochim Biophys Acta. 1997. PMID: 9426204 Review. No abstract available.
• Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.
  Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G, Böhm BO, Schmid RM. Ludwig L, et al. Cancer Res. 2001 Jun 1;61(11):4526-35. Cancer Res. 2001. PMID: 11389085
• Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
  Murakami H, Iwashita T, Asai N, Shimono Y, Iwata Y, Kawai K, Takahashi M. Murakami H, et al. Biochem Biophys Res Commun. 1999 Aug 19;262(1):68-75. doi: 10.1006/bbrc.1999.1186. Biochem Biophys Res Commun. 1999. PMID: 10448070
• [Tyrosine kinase: implications in tumor pathology and therapeutic perspectives].
  Peyrade F, Taillan B, Lebrun C, Baron V, Dujardin P. Peyrade F, et al. Rev Med Interne. 1998 May;19(5):366-72. doi: 10.1016/s0248-8663(98)80114-8. Rev Med Interne. 1998. PMID: 9775178 French.
• Mechanisms involving an expanding erbB/EGF receptor family of tyrosine kinases in human neoplasia.
  Di Fiore PP, Kraus MH. Di Fiore PP, et al. Cancer Treat Res. 1992;61:139-60. doi: 10.1007/978-1-4615-3500-3_7. Cancer Treat Res. 1992. PMID: 1360229 Review. No abstract available.

Cited by

• Synthesis, enzyme inhibition assay, and molecular modeling study of novel pyrazolines linked to 4-methylsulfonylphenyl scaffold: antitumor activity and cell cycle analysis.
  Abdel-Aziz AA, El-Azab AS, Brogi S, Ayyad RR, Alkahtani HM, Abuelizz HA, Al-Suwaidan IA, Al-Obaid AM. Abdel-Aziz AA, et al. RSC Adv. 2024 Jul 12;14(31):22132-22146. doi: 10.1039/d4ra03902e. eCollection 2024 Jul 12. RSC Adv. 2024. PMID: 39005246 Free PMC article.
• Global Gene Expression Profiling and Bioinformatics Analysis Reveal Downregulated Biomarkers as Potential Indicators for Hepatocellular Carcinoma.
  Mestareehi A. Mestareehi A. ACS Omega. 2024 Jun 9;9(24):26075-26096. doi: 10.1021/acsomega.4c01496. eCollection 2024 Jun 18. ACS Omega. 2024. PMID: 38911766 Free PMC article.
• Social and Biological Determinants in Lung Cancer Disparity.
  Brock BA, Mir H, Flenaugh EL, Oprea-Ilies G, Singh R, Singh S. Brock BA, et al. Cancers (Basel). 2024 Jan 31;16(3):612. doi: 10.3390/cancers16030612. Cancers (Basel). 2024. PMID: 38339362 Free PMC article. Review.
• Molecular Docking Study of New Sorafenib Analogues as Platelet-Derived Growth Factor Receptor Inhibitors for the Treatment of Cancer.
  Jihad MI, Mahdi MF. Jihad MI, et al. J Pharm Bioallied Sci. 2023 Jul;15(Suppl 2):S1023-S1026. doi: 10.4103/jpbs.jpbs_244_23. Epub 2023 Jul 11. J Pharm Bioallied Sci. 2023. PMID: 37694099 Free PMC article.
• Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents.
  Kumar A, Bhagat KK, Singh AK, Singh H, Angre T, Verma A, Khalilullah H, Jaremko M, Emwas AH, Kumar P. Kumar A, et al. RSC Adv. 2023 Feb 28;13(10):6872-6908. doi: 10.1039/d3ra00056g. eCollection 2023 Feb 21. RSC Adv. 2023. PMID: 36865574 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database